See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic used to treat various bacterial infections. According to the drug's prescribing information, tigecycline is effective against a wide range of Gram-positive, Gram-negative, and anaerobic bacteria. Specifically, it is indicated for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia.

The bacteria that tigecycline treats include:

* Gram-positive bacteria: Enterococcus faecium (vancomycin-resistant), Staphylococcus aureus (methicillin-resistant), Streptococcus agalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), Streptococcus pyogenes, and Streptococcus pneumoniae (including multi-drug resistant strains [penicillin-resistant pneumococci]).
* Gram-negative bacteria: Acinetobacter baumannii, Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella oxytoca, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
* Anaerobic bacteria: Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Clostridium perfringens, and Peptostreptococcus anaerobius.

It is important to note that tigecycline's effectiveness against these bacteria may vary depending on the specific infection and the susceptibility of the bacteria involved. Healthcare providers should always consider local resistance patterns and obtain cultures when appropriate to guide therapy.

Sources:

1. Tygacil (tigecycline) for injection, for intravenous use [Prescribing Information]. Pfizer Labs. March 2021. Available from: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021858s033lbl.pdf>
2. DrugPatentWatch. Tigecycline. Available from: <https://www.drugpatentwatch.com/drugs/tigecycline>